OptiNose, Inc. (OPTN)
| Market Cap | 209.88M |
| Revenue (ttm) | 43.85M |
| Net Income (ttm) | -100.92M |
| Shares Out | 48.91M |
| EPS (ttm) | -2.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $4.06 |
| Previous Close | $4.12 |
| Change ($) | -0.06 |
| Change (%) | -1.46% |
| Day's Open | 4.17 |
| Day's Range | 4.02 - 4.20 |
| Day's Volume | 497,111 |
| 52-Week Range | 3.20 - 9.01 |
YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, toda...
YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announ...
After COVID-19 slowed their commercial launch, OPTN is doing an exceptional job selling Xhance. Q3 2020 revenues grew ~50% from Q2 & consensus FY2021 revenue estimates forecast 100% growth. Pr...
OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2020 Results - Earnings Call Transcript
Preliminary X HANCE Net Revenue G rowth of 78% C ompared to Third Quarter 2019 and 50% C ompared to Second Quarter 2020
YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
OptiNose has not performed well since its IPO and comes under more pressure, caused by the coronavirus.
Some stock offerings dilute -- but not all.
Shares of Optinose Inc. OPTN, +2.49% plunged 23% in premarket trading Friday, after the specialty pharmaceuticals company, focused on ear, nose, throat and allergy patients, said its stock off...
YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced ...
YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced ...
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2020 Results - Earnings Call Transcript
OptiNose (OPTN) delivered earnings and revenue surprises of -9.80% and -1.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...
YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...
YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...
OptiNose Inc. (NASDAQ: OPTN) shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Company initiates development program using its EDS technology to deliver a nasal “antiseptic” intended to reduce illness and transmission of the COVID-19 virus Company initiates development p...
YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...
YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2020 Results - Earnings Call Transcript
OptiNose, Inc. (OPTN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Optinose, Inc. (OPTN) CEO Peter Miller on Q4 2019 Results - Earnings Call Transcript
OptiNose (OPTN) delivered earnings and revenue surprises of 13.43% and -11.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today anno...
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today anno...
A secondary offering resets the valuation of the ear, nose, and throat specialist.
Optinose, Inc.'s (OPTN) CEO Peter Miller on Q3 2019 Results - Earnings Call Transcript
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are looking for the stocks that have the potential to lift their portfolios to new heights.
YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today re...
YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today a...
YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy sp...
Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $3...
YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today rep...
OptiNose Inc’s (NASDAQ: OPTN) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC C...
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2019 Results - Earnings Call Transcript
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2019 Results - Earnings Call Transcript
OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose Inc. has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald.
Optinose CEO: Building Awareness
Jim Cramer's always sniffing around for new investing ideas and he's caught the scent of an interesting new story in the medical device space. Don't miss his exclusive interview with the CEO o...
About OPTN
OptiNose, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chron... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Oct 13, 2017 |
| CEO Peter Miller | Employees 221 |
| Stock Exchange NASDAQ | Ticker Symbol OPTN |
Financial Performance
In 2019, OptiNose's revenue was $34.63 million, an increase of 390.18% compared to the previous year's $7.07 million. Losses were -$110.05 million, 3.18% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for OptiNose stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 318.72% from the latest price.